Cargando…
PB2132: COPANLISIB PLUS RITUXIMAB-BENDAMUSTINE FOR RELAPSED-REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RECRUITMENT UPDATE ON AN ONGOING PHASE II TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL_COPA-RB)
Autores principales: | Novo, M., Castellino, A., Chiappella, A., Ciccone, G., Balzarotti, M., Arcari, A., Scarpa, E., Tucci, A., Di Renzo, N., Tarantini, G., Gini, G., Moretti, M., Mannina, D., Di Rocco, A., Spina, M., Vitolo, U. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431751/ http://dx.doi.org/10.1097/01.HS9.0000851360.15794.a8 |
Ejemplares similares
-
CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)
por: Gini, Guido, et al.
Publicado: (2021) -
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)
por: Tisi, Maria Chiara, et al.
Publicado: (2019) -
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial
por: Zaccaria, Gian Maria, et al.
Publicado: (2021) -
P1144: RADIOIMMUNOTHERAPY (RIT) VERSUS AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION (ASCT) IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA: A FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III TRIAL.
por: Ladetto, M., et al.
Publicado: (2022) -
Fondazione Italiana Linfomi (FIL) expert consensus on the use of intensity-modulated and image-guided radiotherapy for Hodgkin’s lymphoma involving the mediastinum
por: Filippi, Andrea Riccardo, et al.
Publicado: (2020)